Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
House dust mite (HDM) allergen-specific immune response modulation refers to the complex interplay between HDM allergens and the human immune system, leading to allergic sensitization and inflammation. This process involves both innate and adaptive immunity, with a strong bias toward Th2-type responses that drive conditions such as allergic rhinitis, atopic dermatitis, and asthma. Key molecules include HDM allergens such as Der p 1 and Der p 2, pattern recognition receptors like TLRs, and cytokines such as IL-4, IL-5, and IL-13. Understanding these mechanisms underpins strategies for immunotherapy and other treatments targeting specific molecules/receptors involved in this cascade.
Various, depending on the drug: antihistamines block histamine receptors; corticosteroids suppress inflammation; omalizumab neutralizes IgE; immunotherapy aims to induce tolerance.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on House dust mite allergen-specific immune response modulation (HDM-specific immune modulation).